García-Andrade Fabiola, Vigueras-Villaseñor Rosa María, Chávez-Saldaña Margarita Dolores, Rojas-Castañeda Julio César, Bahena-Ocampo Ivan Uriel, Aréchaga-Ocampo Elena, Flores-Fortis Mauricio, Díaz-Chávez José, Herrera Luis Alonso, Landero-Huerta Daniel Adrian
Laboratorio de Biología de la Reproducción, Instituto Nacional de Pediatría, Ciudad de Mexico 04530, Mexico.
Posgrado en Biología Experimental, Universidad Autónoma Metropolitana, Unidad Iztapalapa, Ciudad de Mexico 09310, Mexico.
Diagnostics (Basel). 2023 Sep 21;13(18):3020. doi: 10.3390/diagnostics13183020.
Cryptorchidism (CO) is a risk factor for the development of testicular germ-cell tumors (TGCT). This is supported by reports showing the persistence of gonocytes in CO patients. These cells are proposed to be related to the development of germ-cell neoplasia in situ (GCNIS), which is considered the precursor stage/lesion of TGCT. Therefore, it is proposed that some patients with CO could express some molecular markers related to TGCT. In this study, we analyzed testicular tissue samples from CO, TGCT, and controls. We determined the expression of POU5F1, PLAP, and KIT by immunohistochemistry and that of the hsa-miR-371-373 cluster, hsa-miR-367, and , , and genes by RT-qPCR. We then carried out a bioinformatic analysis to identify other possible candidate genes as tumor biomarkers. We found that 16.7% (2/12) of the CO patients presented increased expression of POU5F1, KIT, PLAP, hsa-miR-371-373, and hsa-miR-367 and decreased expression of and . Finally, the genes , , and were identified as other possible candidate tumor biomarkers. This is the first report describing the expression of the hsa-miR-371-373 cluster, hsa-miR-367, , and in the testicular tissues of two CO patients with cells immune-positive to POU5F1, PLAP, and KIT, which is similar to what is observed in TGCT.
隐睾症(CO)是睾丸生殖细胞肿瘤(TGCT)发生的一个风险因素。这一点得到了一些报告的支持,这些报告显示CO患者中生殖母细胞持续存在。这些细胞被认为与原位生殖细胞瘤变(GCNIS)的发生有关,而GCNIS被认为是TGCT的前驱阶段/病变。因此,有人提出一些CO患者可能会表达一些与TGCT相关的分子标志物。在本研究中,我们分析了来自CO患者、TGCT患者和对照组的睾丸组织样本。我们通过免疫组织化学确定了POU5F1、PLAP和KIT的表达,并通过RT-qPCR确定了hsa-miR-371-373簇、hsa-miR-367以及[此处原文缺失部分基因名称]基因的表达。然后我们进行了生物信息学分析,以确定其他可能的候选基因作为肿瘤生物标志物。我们发现16.7%(2/12)的CO患者表现出POU5F1、KIT、PLAP、hsa-miR-371-373和hsa-miR-367的表达增加以及[此处原文缺失部分基因名称]和[此处原文缺失部分基因名称]的表达降低。最后,[此处原文缺失部分基因名称]、[此处原文缺失部分基因名称]和[此处原文缺失部分基因名称]基因被确定为其他可能的候选肿瘤生物标志物。这是第一份描述在两名POU5F1、PLAP和KIT免疫阳性细胞的CO患者睾丸组织中hsa-miR-371-373簇、hsa-miR-367以及[此处原文缺失部分基因名称]和[此处原文缺失部分基因名称]表达的报告,这与在TGCT中观察到的情况相似。